Compare Magna International Inc. Common Stock (MGA) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Magna International Inc. Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Magna International Inc. Common Stock trades at $64.38 (market cap $17.25B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Magna International Inc. Common Stock is far larger — about 17.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Magna International Inc. Common Stock pays a 3.07% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Magna International Inc. Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MGA | MRVI | |
|---|---|---|
Market Cap | $17.25B | $977.37M |
Volume | 894,575 | 2,742,564 |
Sector | Consumer Cyclical | Health |
52-Week High | $73.05 | $9.00 |
52-Week Low | $44.65 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $22.29B | $1.08B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Magna International (MGA) trades at $65.31, up 2.75% with a bullish technical signal. The stock shows strong earnings momentum with three consecutive quarterly beats and trades at attractive valuations with P/E of 24.01 and P/S of 0.43. Recent news highlights margin expansion and international growth opportunities, while cash flow remains positive despite increased capital returns.
MGA presents a favorable risk-reward profile with analyst consensus target of $69.20 (5.9% upside) and 43% buy ratings. Key catalysts include Q3 2026 earnings on October 30 and continued margin improvement, though risks include flat auto production and potential tariff impacts on North American operations.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Magna International Inc. Common Stock
Magna International Inc. is a Canada-based automotive supplier that designs, engineers, and manufactures vehicle systems and components, including body and chassis structures, seating, powertrain, and electronics, and provides complete-vehicle engineering and contract assembly, with manufacturing operations in 28 countries.
Read more on MGA →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
